2cureX AB (publ) (STO:2CUREX)
Sweden · Delayed Price · Currency is SEK 1.872
+0.072 (4.00%)
Jul 24, 2026, 4:23 PM CET
2cureX AB Revenue
In the year 2025, 2cureX AB had annual revenue of 10.00K SEK with 400.00% growth. 2cureX AB had revenue of 1.50K in the quarter ending December 31, 2025.
Revenue
10.00K
Revenue Growth
+400.00%
P/S Ratio
30.22
Revenue / Employee
141.14K
Employees
14
Market Cap
59.72M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 10.00K | 8.00K | 400.00% |
| Dec 31, 2024 | 2.00K | -2.95M | -99.93% |
| Dec 31, 2023 | 2.95M | -422.00K | -12.53% |
| Dec 31, 2022 | 3.37M | -4.02M | -54.42% |
| Dec 31, 2021 | 7.39M | -8.00M | -51.98% |
| Dec 31, 2020 | 15.39M | 3.41M | 28.45% |
| Dec 31, 2019 | 11.98M | 4.31M | 56.12% |
| Dec 31, 2018 | 7.68M | 3.77M | 96.64% |
| Dec 31, 2017 | 3.90M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Magle Chemoswed Holding AB | 273.25M |
| Fluicell AB | 20.15M |
| ExpreS2ion Biotech Holding AB | 16.12M |
| AcouSort AB | 10.05M |
| Spago Nanomedical AB | 4.38M |
| Pila Pharma AB | 1.13M |
| Alligator Bioscience AB | 520.00K |
| OncoZenge AB | 71.00K |
2cureX AB News
- 2 months ago - 2cureX AB Transcript: Investor update - Transcripts
- 5 months ago - 2cureX AB Quarterly report: H2 2025 - Filings
- 5 months ago - 2cureX AB Annual report: H2 2025 - Filings
- 1 year ago - 2cureX AB Quarterly report: H1 2025 - Filings